Siva Swapna Kasarla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siva Swapna Kasarla has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antonia Fecke
Leibniz-Institut für Analytische Wissenschaften─ISAS─e.V., Otto-Hahn-Str. 6b, Dortmund 44227, Germany
2 shared publications - Prasad Phapale
Aarhus University
2 shared publications Jianxu Chen
Leibniz-Institut für Analytische Wissenschaften─ISAS─e.V., Otto-Hahn-Str. 6b, Dortmund 44227, Germany
1 shared publication- Karl William Smith
Leibniz-Institut für Analytische Wissenschaften—ISAS—e.V, Dortmund, Germany
1 shared publication Lennart Kowitz
Leibniz-Institut für Analytische Wissenschaften─ISAS─e.V., Otto-Hahn-Str. 6b, Dortmund 44227, Germany
1 shared publication- Madhu Dikshit
Division of Pharmacology, Central Drug Research Institute, Lucknow 226001, India
1 shared publication
Latest Publications
- 6 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 11980-11985
MSI-Explorer: Napari-Powered Tool for Mass Spectrometry Imaging Data Analysis
Mass spectrometry imaging (MSI) enables label-free spatial localization of biomolecules from single cells to whole tissues, making it a key technology in the growing fields of spatial omics. However, a lack of comprehensive open-source tools for MSI data analysis, visualization, and quantification has hindered its broader adoption. Napari, a widely used interactive Python-based image analysis platform, currently lacks native support for MSI data, limiting its applications in MSI research. To address this gap, we present MSI-Explorer, the first napari plugin that provides an interactive and user-friendly interface for MSI data processing, spectral analysis, molecular annotation, and quantification. By integrating napari's advanced visualization capabilities with MSI-specific functionalities, MSI-Explorer provides image curation, multimodal, and efficient analysis of MSI data sets. As the first dedicated MSI plugin for napari, MSI-Explorer bridges the gap between spatial metabolomics and the broader bioimaging research community, promoting open, accessible, and integrated MSI data analysis.
- 6 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 11980-11985
MSI-Explorer: Napari-Powered Tool for Mass Spectrometry Imaging Data Analysis
Mass spectrometry imaging (MSI) enables label-free spatial localization of biomolecules from single cells to whole tissues, making it a key technology in the growing fields of spatial omics. However, a lack of comprehensive open-source tools for MSI data analysis, visualization, and quantification has hindered its broader adoption. Napari, a widely used interactive Python-based image analysis platform, currently lacks native support for MSI data, limiting its applications in MSI research. To address this gap, we present MSI-Explorer, the first napari plugin that provides an interactive and user-friendly interface for MSI data processing, spectral analysis, molecular annotation, and quantification. By integrating napari's advanced visualization capabilities with MSI-specific functionalities, MSI-Explorer provides image curation, multimodal, and efficient analysis of MSI data sets. As the first dedicated MSI plugin for napari, MSI-Explorer bridges the gap between spatial metabolomics and the broader bioimaging research community, promoting open, accessible, and integrated MSI data analysis.
- Open Access
- 12 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Improved MALDI-MS Imaging of Polar and 2H-1 Labeled Metabolites in Mouse Organ Tissues
Imaging small polar metabolites and analyzing their in vivo dynamics with stable isotope labeled (SIL) tracing through various biochemical pathways, including citric acid (TCA) cycle, glycolysis, and amino acid metabolism, has gained substantial interest over the years. However, imaging these small polar metabolites across different tissue types is limited due to their lower ionization efficiencies and ion suppression from larger abundant biomolecules. These challenges can be further exacerbated with SIL studies, which require improvements in sample preparation and method sensitivity. Solvent pretreatments before matrix application on a tissue section have the potential to improve the sensitivity of metabolite imaging, however, they are not yet widely optimized across tissue types. Further there is recurring concern about metabolite delocalization from such wash treatments which require ‘spatial validation’. Here, we optimized a simple ‘basic hexane’ wash method that improved sensitivity up to several folds for a broad range of polar and 2H labeled metabolites across five different mouse organ tissues (kidney, heart, brain, liver, and brown adipose tissue). Notably, we provided region-specific quantification of 51 metabolites using laser-microdissection (LMD)-LC-MS/MS to validate their localization observed in MALDI-MSI analysis after basic hexane wash. Overall, we reported an improved MALDI-MSI sample pretreatment method with ‘spatial validation’ workflow for sensitive and robust imaging of polar metabolite distributions in mouse organs.
- 12 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessImproved MALDI-MS Imaging of Polar and 2H-1 Labeled Metabolites in Mouse Organ Tissues
Imaging small polar metabolites and analyzing their in vivo dynamics with stable isotope labeled (SIL) tracing through various biochemical pathways, including citric acid (TCA) cycle, glycolysis, and amino acid metabolism, has gained substantial interest over the years. However, imaging these small polar metabolites across different tissue types is limited due to their lower ionization efficiencies and ion suppression from larger abundant biomolecules. These challenges can be further exacerbated with SIL studies, which require improvements in sample preparation and method sensitivity. Solvent pretreatments before matrix application on a tissue section have the potential to improve the sensitivity of metabolite imaging, however, they are not yet widely optimized across tissue types. Further there is recurring concern about metabolite delocalization from such wash treatments which require ‘spatial validation’. Here, we optimized a simple ‘basic hexane’ wash method that improved sensitivity up to several folds for a broad range of polar and 2H labeled metabolites across five different mouse organ tissues (kidney, heart, brain, liver, and brown adipose tissue). Notably, we provided region-specific quantification of 51 metabolites using laser-microdissection (LMD)-LC-MS/MS to validate their localization observed in MALDI-MSI analysis after basic hexane wash. Overall, we reported an improved MALDI-MSI sample pretreatment method with ‘spatial validation’ workflow for sensitive and robust imaging of polar metabolite distributions in mouse organs.
- Open Access
- 30 June 2022
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 37 (3) , 392-407
Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer
Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past few decades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is highly questionable in disease states due to flexible alterations in the enzymes responsible for their metabolism. For instance, CYP3A4 plays a crucial role in the biotransformation of vitamin D and other drug substances. Food-drug and/or drug-drug interactions, the disease state, genetic polymorphism, age, sex, diet, and environmental factors all influence CYP3A4 activity. Genetic polymorphisms in CYP450-encoding genes have received considerable attention in the past few decades due to their extensive impact on the pharmacokinetic and dynamic properties of drugs and endogenous substances. In this review, we focused on CYP3A4 polymorphisms and their interplay with vitamin D metabolism and summarized the role of vitamin D in calcium homeostasis, bone diseases, diabetes, cancer, other diseases, and drug substances. We also reviewed clinical observations pertaining to CYP3A4 polymorphisms among the aforementioned disease conditions. In addition, we highlighted the future perspectives of studying the pharmacogenetics of CYP3A4, which may have potential clinical significance for developing novel diagnostic genetic markers that will ascertain disease risk and progression.
- 30 June 2022
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 37 (3) , 392-407
Open AccessInterplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer
Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past few decades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is highly questionable in disease states due to flexible alterations in the enzymes responsible for their metabolism. For instance, CYP3A4 plays a crucial role in the biotransformation of vitamin D and other drug substances. Food-drug and/or drug-drug interactions, the disease state, genetic polymorphism, age, sex, diet, and environmental factors all influence CYP3A4 activity. Genetic polymorphisms in CYP450-encoding genes have received considerable attention in the past few decades due to their extensive impact on the pharmacokinetic and dynamic properties of drugs and endogenous substances. In this review, we focused on CYP3A4 polymorphisms and their interplay with vitamin D metabolism and summarized the role of vitamin D in calcium homeostasis, bone diseases, diabetes, cancer, other diseases, and drug substances. We also reviewed clinical observations pertaining to CYP3A4 polymorphisms among the aforementioned disease conditions. In addition, we highlighted the future perspectives of studying the pharmacogenetics of CYP3A4, which may have potential clinical significance for developing novel diagnostic genetic markers that will ascertain disease risk and progression.
- Open Access
- 29 December 2021
- Published by Springer Nature in Research Square
CYP-450 Mediated Herb-Drug Interactions of Ashwagandha and AYUSH-64 Used in COVID-19 Integrative Management: A Case Example of Remdesivir
AimWithania somnifera Dunal (WS), known as Ashwagandha and AYUSH-64, a polyherbal formulation are repurposed for the management of COVID-19. The extensive use of these botanicals as home remedy along with other drugs for managing multifarious disease conditions is increasing over nations. This raises high chances of herb-drug interactions (HDIs) which may be beneficial, harmful, or even fatal. Therefore, current study aimed to explore the CYP mediated herb-drug interactions (HDIs) of Ashwagandha and AYUSH-64 along with case example of remdesivir to harness the best of these HDIs for integrative management of COVID-19Materials and MethodsThe aqueous extract of Ashwagandha and AYUSH-64 were characterized by LC-MS/MS. The in-silico pharmacokinetic (ADME) parameters were studied by using ADME tool. The in-vitro CYP-450 (CYP3A4, 2C8, 2D6) inhibition studies of WS and AYUSH-64 alone and in combination with a remdesivir were carried out resembling clinically scenario.ResultsTotal of 11 and 24 phytoconstituents were identified from the aqueous extract of Aswagandha and AYUSH-64. The in-silico ADME studies revealed that most of the phytoconstituents showed good oral bioavailability, drug likeliness, GI affinity and some of them displayed CYP-450 inhibitory activity. The in-vitro CYP-450 studies of remdesivir showed moderate inhibitory effect on CYP3A4, 2C8, 2D6. The aqueous extract of Aswagandha did not show any inhibitory activity towards all the studied CYP’s alone and in combination with remdesivir (IC50 >100µg/ml). Whereas, AYUSH-64 also followed the same trend but showed moderate inhibitory effect on CYP2C8 (IC50 ConclusionAswagandha did not exhibit HDIs with the CYP3A4, CYP2C8 and CYP2D6 thereby seem to be safe to co-administer with respective substrates. Whereas, AYUSH-64 only showed moderate HDIs towards CYP2C8 substrate among studied CYP enzymes. Caution is therefore warranted for prescribing AYUSH 64 along with CYP2C8 substrate drugs.
- 29 December 2021
- Published by Springer Nature in Research Square
Open AccessCYP-450 Mediated Herb-Drug Interactions of Ashwagandha and AYUSH-64 Used in COVID-19 Integrative Management: A Case Example of Remdesivir
AimWithania somnifera Dunal (WS), known as Ashwagandha and AYUSH-64, a polyherbal formulation are repurposed for the management of COVID-19. The extensive use of these botanicals as home remedy along with other drugs for managing multifarious disease conditions is increasing over nations. This raises high chances of herb-drug interactions (HDIs) which may be beneficial, harmful, or even fatal. Therefore, current study aimed to explore the CYP mediated herb-drug interactions (HDIs) of Ashwagandha and AYUSH-64 along with case example of remdesivir to harness the best of these HDIs for integrative management of COVID-19Materials and MethodsThe aqueous extract of Ashwagandha and AYUSH-64 were characterized by LC-MS/MS. The in-silico pharmacokinetic (ADME) parameters were studied by using ADME tool. The in-vitro CYP-450 (CYP3A4, 2C8, 2D6) inhibition studies of WS and AYUSH-64 alone and in combination with a remdesivir were carried out resembling clinically scenario.ResultsTotal of 11 and 24 phytoconstituents were identified from the aqueous extract of Aswagandha and AYUSH-64. The in-silico ADME studies revealed that most of the phytoconstituents showed good oral bioavailability, drug likeliness, GI affinity and some of them displayed CYP-450 inhibitory activity. The in-vitro CYP-450 studies of remdesivir showed moderate inhibitory effect on CYP3A4, 2C8, 2D6. The aqueous extract of Aswagandha did not show any inhibitory activity towards all the studied CYP’s alone and in combination with remdesivir (IC50 >100µg/ml). Whereas, AYUSH-64 also followed the same trend but showed moderate inhibitory effect on CYP2C8 (IC50 ConclusionAswagandha did not exhibit HDIs with the CYP3A4, CYP2C8 and CYP2D6 thereby seem to be safe to co-administer with respective substrates. Whereas, AYUSH-64 only showed moderate HDIs towards CYP2C8 substrate among studied CYP enzymes. Caution is therefore warranted for prescribing AYUSH 64 along with CYP2C8 substrate drugs.